Keith Tapper
Stock Analyst at BMO Capital
(1.06)
# 3,528
Out of 4,711 analysts
5
Total ratings
40%
Success rate
-8.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $60 → $45 | $22.64 | +98.76% | 3 | Nov 20, 2024 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $1.85 | +170.27% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $16.87 | +83.76% | 1 | Jun 27, 2024 |
Neurogene
Nov 20, 2024
Maintains: Outperform
Price Target: $60 → $45
Current: $22.64
Upside: +98.76%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $1.85
Upside: +170.27%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $16.87
Upside: +83.76%